Summary
GlobalData's report, "Pulmonary Arterial Hypertension (PAH)-Pipeline Assessment and Market Forecasts to 2016" provides an essential source of information and analysis on the global PAH market. The report identifies the key trends shaping and driving the global PAH market. The report also provides insight on the competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global PAH sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData valued the global Pulmonary Arterial Hypertension (PAH) market to be worth $2,653m in 2009. According to the Venice 2003 revised classification system, PAH is categorized as World Health Organization (WHO) Group I-PAH. Prior to 2001, no drug was approved for the treatment of PAH. Only supportive care medication such as anticoagulants, diuretics, oxygen, digoxin and calcium channel blockers was given to the patients. In 2001, the US Food and Drug Administration (FDA) approved Tracleer as the treatment for patients with PAH. This drug is a registered trademark of Actelion Ltd. The sales of Tracleer grew rapidly due to a high patient switch over from off-label drugs to Tracleer. The drug has a better efficacy profile compared to the previously used off-label drugs.

The FDA also approved three more drugs, Remodulin, Ventavis, and Revatio in 2002, 2004 and 2005 respectively for the treatment of PAH. However, these three drugs accounted for only a 24% market share to PAH market in 2005. Between 2005 and 2009, the PAH market grew at a Compound Annual Growth Rate (CAGR) of 39.2% and recorded revenues of $2,653m in 2009. According to GlobalData analysis, the PAH market is forecast to grow at a CAGR of 5% annually over the next six years to reach $3,569m by 2015. Tracleer, the major revenue generating drug of the PAH market is expected to go off patent by 2015. The patent expiry of this drug will be a major barrier for the market growth. Until this time, the growth of the PAH market is primarily attributed to increased competition among existing products, the release of new and enhanced treatment options, and the development of safer and more efficacious therapies. In 2009, Actelion Ltd, with its key drug Tracleer, was the leading player in the global PAH market.

Table of Contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Pulmonary Arterial Hypertension Market: Market Characterization 6
2.1 Overview 6
2.2 Pulmonary Arterial Hypertension Market Size 6
2.3 Pulmonary Arterial Hypertension Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Pulmonary Arterial Hypertension Market 8
2.4.1 Drivers for the Pulmonary Arterial Hypertension Market 8
2.4.2 Barriers for the Pulmonary Arterial Hypertension Market 9
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 11
3 Pulmonary Arterial Hypertension Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Marketed Products in the Pulmonary Arterial Hypertension Market 13
3.3.1 Tracleer 13
3.3.2 Remodulin 14
3.3.3 Revatio 15
3.3.4 Ventavis 16
3.3.5 Letairis 17
3.3.6 Adcirca 19
3.4 Key Takeaway 23
4 Pulmonary Arterial Hypertension Market: Pipeline Assessment 24
4.1 Overview 24
4.2 Strategic Pipeline Assessment 24
4.2.1 Technology Trends Analytical Framework 24
4.3 Pulmonary Arterial Hypertension Therapeutics-Promising Drugs under Clinical Development 26
4.4 Molecule Profile for Promising Drugs under Clinical Development 27
4.4.1 Iloprost 27
4.4.2 ACT-064992 27
4.4.3 Oral Treprostinil 28
4.4.4 ACT-293987 28
4.4.5 Riociguat (BAY63-2521) 29
4.5 Pulmonary Arterial Hypertension Pipeline-Pipeline by Clinical Phases of Development 30
4.5.1 Pulmonary Arterial Hypertension Therapeutics-Phase III Clinical Pipeline 31
4.5.2 Pulmonary Arterial Hypertension Therapeutics-Phase II Clinical Pipeline 32
4.5.3 Pulmonary Arterial Hypertension Therapeutics-Phase I Clinical Pipeline 34
4.5.4 Pulmonary Arterial Hypertension Therapeutics-Preclinical Pipeline 34
4.6 Discontinued/Suspended Drugs for Pulmonary Arterial Hypertension 35
4.7 Key Takeaway 35
5 Global Pulmonary Arterial Hypertension Market: Implications for Future Market Competition 36
6 Pulmonary Arterial Hypertension Market: Future Players in the Pulmonary Arterial Hypertension Market 38
6.1 Introduction 38
6.2 Actelion Ltd. 39
6.2.1 Company Overview 39
6.2.2 Business Description 39
6.2.3 Company Pipeline 40
6.3 United Therapeutics Corporation 40
6.3.1 Company Overview 40
6.3.2 Business Description 40
6.3.3 Company Pipeline 41
6.4 Bayer AG 41
6.4.1 Company Overview 41
6.4.2 Business Description 41
6.4.3 Company Pipeline 42
6.5 Gilead Sciences 42
6.5.1 Company Overview 42
6.5.2 Business Description 43
6.5.3 Company Pipeline 44
6.6 Pfizer Inc. 44
6.6.1 Company Overview 44
6.6.2 Business Description 44
6.6.3 Company Pipeline 45
6.7 Novartis AG 45
6.7.1 Company Overview 45
6.7.2 Business Description 45
6.7.3 Company Pipeline 46
6.8 Bristol-Myers Squibb 46
6.8.1 Company Overview 46
6.8.2 Business Description 47
6.8.3 Company Pipeline 47
6.9 Sanofi-Aventis 47
6.9.1 Company Overview 47
6.9.2 Business Description 48
6.9.3 Company Pipeline 48
6.10 GlaxoSmithKline 48
6.10.1 Company Overview 48
6.10.2 Business Description 49
6.10.3 Company Pipeline 49
7 Pulmonary Arterial Hypertension Market: Appendix 50
7.1 Definitions 50
7.2 Abbreviations 50
7.3 Research Methodology 52
7.3.1 Coverage 52
7.3.2 Secondary Research 53
7.3.3 Forecasting 53
7.3.4 Primary Research 56
7.3.5 Expert Panels 56
7.4 Contact Us 56
7.5 Disclaimer 56
7.6 Sources 57

List of Tables
1.1 List of Tables
Table 1:  Pulmonary Arterial Hypertension Market, Global, Revenues ($m), 2005-2009 7
Table 2:  Pulmonary Arterial Hypertension Market, Global, Revenues ($m), 2009-2016 8
Table 3: Major Marketed Products Comparison in Pulmonary Arterial Hypertension Market, 2010 21
Table 4:    Pulmonary Arterial Hypertension Therapeutics-Most Promising Drugs Under Clinical Development, 2010 26
Table 5:  Pulmonary Arterial Hypertension Therapeutics-Phase III Clinical Pipeline, 2010 31
Table 6:  Pulmonary Arterial Hypertension Therapeutics-Phase II Clinical Pipeline, 2010 32
Table 7:  Pulmonary Arterial Hypertension Therapeutics-Phase I Clinical Pipeline, 2010 34
Table 8:  Pulmonary Arterial Hypertension Therapeutics-Preclinical Pipeline, 2010 34
Table 9:  List of Discontinued/Suspended Drugs for Pulmonary Arterial Hypertension, 2010 35
Table 10: Actelion Ltd.-Pulmonary Arterial Hypertension Pipeline, 2010 40
Table 11: United Therapeutics Ltd.-Pulmonary Arterial Hypertension Pipeline, 2010 41
Table 12: Bayer AG-Pulmonary Arterial Hypertension Pipeline, 2010 42
Table 13: Gilead Sciences-Pulmonary Arterial Hypertension Pipeline, 2010 44
Table 14: Pfizer Inc.-Pulmonary Arterial Hypertension Pipeline, 2010 45
Table 15: Novartis AG-Pulmonary Arterial Hypertension Pipeline, 2010 46
Table 16: Bristol-Myers Squibb-Pulmonary Arterial Hypertension Pipeline, 2010 47
Table 17: Sanofi-Aventis-Pulmonary Arterial Hypertension Pipeline, 2010 48
Table 18: GlaxoSmithKline plc.-Pulmonary Arterial Hypertension Pipeline, 2010 49

List of Figures
1.2 List of Figures
Figure 1:  Global Pulmonary Arterial Hypertension Market Revenues and Forecast, 2005-2016 7
Figure 2:  Pulmonary Arterial Hypertension, Global, Market Forecast, 2009-2016 8
Figure 3:  Opportunity and Unmet Need in the Pulmonary Arterial Hypertension Market, 2010 10
Figure 4:    Strategic Competitor Assessment of the Major Marketed Products in Pulmonary Arterial Hypertension Therapeutics, 2010 13
Figure 5: Technology Trends Analytic Framework-Pulmonary Arterial Hypertension Market, 2010 24
Figure 6: Technology Trends Analytic Framework of the Pulmonary Arterial Hypertension Pipeline-Description, 2010 25
Figure 7: Pulmonary Arterial Hypertension Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8:  Pulmonary Arterial Hypertension Pipeline by Phase of Clinical Development, 2010 30
Figure 9: Implications for Future Market Competition in Pulmonary Arterial Hypertension, 2010 36
Figure 10: Pulmonary Arterial Hypertension Therapeutics Market-Clinical Pipeline by Company, 2010 38
Figure 11: Pulmonary Arterial Hypertension, Global, Companies That Have the Highest Number of Molecules in the Pipeline, 2010 39
Figure 12: GlobalData Methodology 52
Figure 13: GlobalData Market Forecasting Model 55